Ledeberg, Belgium

Lieven Huang

This inventor holds 1 USPTO granted patent. Top assignees: University of Ghent, Vib Vzw, Vrije Universiteit Brussel. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lieven Huang. Retrieved from https://idiyas.com/inventor/lieven-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Lieven Huang

Introduction

Lieven Huang is a notable inventor based in Ledeberg, Belgium. He has made significant contributions to the field of medical science, particularly in the treatment of tumors. His innovative approach has led to the development of a unique treatment method that targets specific types of cancer.

Latest Patents

Lieven Huang holds 1 patent for his invention titled "Treatment of EGFR-dependent tumors by ABIN (a20-binding inhibitor of NF kappab)." This patent focuses on the treatment of epidermal growth factor-family receptor (ErbB)-dependent tumors. The invention specifically relates to the use of ABIN for preparing a medicament that inhibits epidermal growth factor (EGF)-induced proliferation, thereby providing a therapeutic option for treating ErbB-dependent tumors.

Career Highlights

Throughout his career, Lieven Huang has worked with various esteemed organizations. Notably, he has been associated with Vib Vzw and Universiteit Gent, where he has contributed to research and development in his field. His work has been instrumental in advancing the understanding and treatment of cancer.

Collaborations

Lieven Huang has collaborated with several professionals in his field, including Rudi Beyaert and Hilde Revets. These collaborations have enriched his research and have led to significant advancements in cancer treatment methodologies.

Conclusion

Lieven Huang's innovative work in the treatment of EGFR-dependent tumors showcases his dedication to improving medical science. His contributions are paving the way for new therapeutic options in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…